<?xml version="1.0" encoding="UTF-8"?>
 <!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
 <article article-type="research-article" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
   <journal-meta>
    <journal-id journal-id-type="publisher-id">SM</journal-id>
    <journal-title-group>
     <journal-title>Salud Mental</journal-title>
     <abbrev-journal-title>sm</abbrev-journal-title>
    </journal-title-group>
    <issn pub-type="epub">0185-3325</issn>
    <publisher>
     <publisher-name>Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz</publisher-name>
    </publisher>
   </journal-meta>
   <article-meta>
    <article-id pub-id-type="publisher-id">SM4562</article-id>
    <article-id pub-id-type="doi">10.17711/SM.0185-3325.2018.009</article-id>
    <article-categories>
     <subj-group subj-group-type="heading">
      <subject>Original article</subject>
     </subj-group>
    </article-categories>
    <title-group>
     <article-title>Validity and reliability of the Neurobehavioral Evaluation of Infant Development (VANEDELA). Screening Instrument from one to 24 months in primary health care in Mexico</article-title>
     <trans-title-group xml:lang="es">
      <trans-title>Validez y confiabilidad del instrumento de tamizaje Valoración Neuroconductual del Desarrollo del Lactante (VANEDELA) de uno a 24 meses en el primer nivel de atención en México</trans-title>
     </trans-title-group>
     <alt-title alt-title-type="running-head">Validity and reliability of the Neurobehavioral Evaluation of Infant Development (VANEDELA). Screening Instrument from one to 24 months in primary health care in Mexico</alt-title>
    </title-group>
    <contrib-group>
     <contrib contrib-type="author">
      <name>
       <surname>Rosa Ivone</surname>
       <given-names>Martínez-Vázquez</given-names>
      </name>
      <xref ref-type="aff" rid="AF0001">1</xref>
      <xref ref-type="aff" rid="AF0002">2</xref>
     </contrib>
     <contrib contrib-type="author">
      <name>
       <surname>Gerardo Alberto</surname>
       <given-names>Alvarado-Ruiz</given-names>
      </name>
      <xref ref-type="aff" rid="AF0001">1</xref>
      <xref ref-type="aff" rid="AF0002">2</xref>
     </contrib>
     <contrib contrib-type="author">
      <name>
       <surname>Carmen</surname>
       <given-names>Sánchez-Pérez</given-names>
      </name>
      <xref ref-type="aff" rid="AF0001">1</xref>
      <xref ref-type="aff" rid="AF0002">2</xref>
     </contrib>
     <contrib contrib-type="author">
      <name>
       <surname>Patricia</surname>
       <given-names>Muñoz Ledo-Rábago</given-names>
      </name>
      <xref ref-type="aff" rid="AF0002">2</xref>
     </contrib>
    </contrib-group>
    <aff id="AF0001">
     <label>1</label>
     Laboratorio de Seguimiento del Neurodesarrollo, Dirección de Investigación, Instituto Nacional de Pediatría, Ciudad de México, México.
    </aff>
    <aff id="AF0002">
     <label>2</label>
     Universidad Autónoma Metropolitana, Ciudad de México, México.
    </aff>
    <author-notes>
     <corresp id="cor1">
      Correspondence: Rosa Ivone Martínez-Vázquez Laboratorio de Seguimiento del Neurodesarrollo, Instituto Nacional de Pediatría.  Insurgentes Sur 3000-C, Col. Insurgentes Cuicuilco, Del. Coyoacán, C.P. 04530, Ciudad de México, México. Phone: 1084 0900 ext. 1438. Email: ivone.martinez.vazquez@gmail.com
      <email xlink:href="ivone.martinez.vazquez@gmail.com">ivone.martinez.vazquez@gmail.com</email>
     </corresp>
    </author-notes>
    <pub-date pub-type="epub-ppub">
     <month>05</month>
     <year>2018</year>
    </pub-date>
    <volume>41</volume>
    <issue>2</issue>
    <fpage>57</fpage>
    <lpage>63</lpage>
    <history>
     <date date-type="received">
      <day>30</day>
      <month>08</month>
      <year>2017</year>
     </date>
     <date date-type="accepted">
      <day>21</day>
      <month>04</month>
      <year>2018</year>
     </date>
     <date date-type="Publicado on-line">
      <day>01</day>
      <month>05</month>
      <year>2018</year>
     </date>
    </history>
    <permissions>
     <copyright-statement>© 2001-2015. Todos los Derechos Reservados a Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz</copyright-statement>
     <copyright-year>2018</copyright-year>
     <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
      <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial (by-nc) Spain 3.0 License.</license-p>
     </license>
    </permissions>
    <abstract xml:lang="en">Introduction. Early identification of developmental delays or disabilities in children is a challenge and a global concern. In Mexico, the prevalence of childhood disability is 6%, and it is estimated that 25% of the unattended delays will have consequences on their potential. VANEDELA is a rapid screening test to detect and prevent developmental disorders in primary health care. Objective. To determine the external validity and test-retest reliability of the behavioral (DB) and reflex (DR) developmental formats of the VANEDELA screening test, compared with the diagnostic test of Gesell&rsquo;s Developmental Schedule Test. Method. Descriptive, transversal, and prospective study in 379 infants aged one to 24 months attending the Neurodevelopment Monitoring Laboratory / INP and the ISSSTE Tlalpan Family Medicine Clinic from 2011 to 2014. Measurements: A set of four aspects was evaluated including validity by external criteria: sensitivity, specificity, positive-negative predictive criteria, and test-retest reliability. Results. In the DB format, we found a 79% - 89% sensitivity (S) and a 83% - 95% specificity (Sp). In the DR format, a 18% - 35% sensitivity and a 81% - 96% specificity were found. Using both DB-DR formats, we found a 82% - 89% sensitivity and 72% to 91% specificity, and a test-retest reliability .62-1. Discussion and conclusion. The VANEDELA increased its validity parameters with respect to the previous assessment with adequate stability. The DB formats and the DB-DR combination of VANEDELA have an adequate validity based on external criteria, making them suitable for use in primary health care.</abstract>
    <trans-abstract xml:lang="es">Introducci&oacute;n. La identificaci&oacute;n temprana de retrasos o discapacidades del desarrollo en los ni&ntilde;os es un reto y una preocupaci&oacute;n mundial. En M&eacute;xico, la prevalencia de discapacidad infantil es del 6% y se estima que un 25% de los retrasos no atendidos tendr&aacute;n consecuencias en su potencial alcanzado. El VANEDELA es una prueba de tamizaje r&aacute;pido para detectar y prevenir alteraciones del desarrollo en el primer nivel de atenci&oacute;n. Objetivo. Determinar la validez (criterio externo) y confiabilidad (test-retest) de los formatos de conductas (CD) y reacciones del desarrollo (RD) de la prueba de tamizaje VANEDELA, contrastado con la Prueba Diagn&oacute;stica de Desarrollo de Gesell. M&eacute;todo. Estudio descriptivo, transversal y prospectivo en 379 lactantes de uno a 24 meses que asistieron al Laboratorio de Seguimiento del Neurodesarrollo del INP y la Cl&iacute;nica de Medicina Familiar Tlalpan del ISSSTE de 2011 a 2012. Mediciones: Validez por criterio externo, sensibilidad y especificidad, validez predictiva positiva y negativa; confiabilidad test-retest (intervalo de siete d&iacute;as). Resultados. En el formato CD, se encontr&oacute; sensibilidad (S) de 79% a 89% y especificidad (E) de 83% a 95%. Utilizando ambos formatos CD-RD, se encontraron una sensibilidad de 82% a 89% y una especificidad de 72% a 91%. Test-retest .62-1. Discusi&oacute;n y conclusi&oacute;n. El VANEDELA aument&oacute; sus par&aacute;metros de validez con respecto a la valoraci&oacute;n anterior, estabilidad adecuada. Los formatos CD y la combinaci&oacute;n CD-RD del VANEDELA poseen una adecuada validez por criterio externo y estabilidad test-retest, para ser utilizada en el primer nivel de atenci&oacute;n.</trans-abstract>
    <kwd-group xml:lang="en">
     <kwd>Screening</kwd>
     <kwd>infant development</kwd>
     <kwd>diagnostic tests</kwd>
     <kwd>test-retest</kwd>
     <kwd>VANEDELA</kwd>
    </kwd-group>
    <kwd-group xml:lang="es">
     <kwd>Tamizaje</kwd>
     <kwd>desarrollo infantil</kwd>
     <kwd>diagnóstico del test</kwd>
    </kwd-group>
   </article-meta>
  </front>
 </article>

